| Autor: |
Meng-Ju Lin, Tung-Hung Su, Chun-Jen Liu, Hung-Chih Yang, Chi-Ling Chen, Jyh-Ming Liou, Tai-Chung Tseng, Chen-Hua Liu, Chun-Ming Hong, Pei-Jer Chen, Jia-Horng Kao |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Journal of the Formosan Medical Association, Vol 122, Iss 7, Pp 564-573 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
0929-6646 |
| DOI: |
10.1016/j.jfma.2023.02.002 |
| Popis: |
Background/purpose: Distinct hepatitis relapse has been observed after discontinuing entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in chronic hepatitis B (CHB) patients. End-of-therapy (EOT) serum cytokines were compared and used for outcome prediction. Methods: A total of 80 non-cirrhotic CHB patients in a tertiary medical center in Taiwan who discontinued ETV (n = 51) or TDF (n = 29) therapy after fulfilling the APASL guidelines were prospectively enrolled. Serum cytokines were measured at EOT and 3rd month afterwards. Multivariable analysis was performed to predict virological relapse (VR, HBV DNA >2000 IU/mL), clinical relapse (CR, VR and alanine aminotransferase > 2-fold upper limit of normal) and hepatitis B surface antigen (HBsAg) seroclearance. Results: Compared with TDF group, ETV stoppers had greater interleukin 5 (IL-5), IL-12 p70, IL-13, IL-17 A and tumor necrosis factor alpha (TNF-alpha) (all P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
